Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 8/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23336436 | 0.90 | CFTR (0.46) | CFTREGLN2BTKKDM4EPOLB | |
| SCHEMBL29840296 | 0.90 | CFTR (0.46) | CFTREGLN2BTKKDM4EPOLB | |
| SCHEMBL27167861 | 0.85 | CFTR (0.42) | CFTREGLN2KDM4E | |
| SCHEMBL27168183 | 0.83 | CFTR (0.41) | CFTREGLN2GRM2 | |
| SCHEMBL24791635 | 0.76 | BDKRB1 (0.44) | BTKGRM2 | |
| SCHEMBL30083497 | 0.76 | BDKRB1 (0.44) | BTKGRM2 | |
| SCHEMBL18752916 | 0.76 | GRM2 (0.42) | BTKGRM2 | |
| SCHEMBL23303990 | 0.76 | MEN1 (0.41) | CFTRBTKKDM4EPOLB | |
| SCHEMBL27428530 | 0.75 | BACE1 (0.46) | BTKGRM2 | |
| SCHEMBL27167851 | 0.75 | CFTR (0.43) | CFTRBTKKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117580592-A | Compounds for targeting bruton's tyrosine kinase degradation | 渤健马萨诸塞州股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CFTR 1076/4885EGLN2 4675/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.